Tourmaline Bio to Present at Upcoming Investor Conferences
31 oct. 2024 07h30 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio to Present at Upcoming Investor Conferences
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call
31 oct. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...
A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)
30 oct. 2024 08h01 HE
|
A Race Against Blindness
A Race Against Blindness grants $1M to Axovia Therapeutics for a clinical trial targeting blindness and obesity in Bardet-Biedl Syndrome.
A Family’s Race To Treat Childhood Blindness: A Race Against Blindness Grants $1 Million to Bardet-Biedl Syndrome Research
30 oct. 2024 08h00 HE
|
A Race Against Blindness
Arizona Family’s Journey: A Race Against Blindness grants $1M to Bardet-Biedl Syndrome research, fueling hope and potential cures for childhood blindness.
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
15 oct. 2024 08h30 HE
|
Knight Therapeutics
MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate,...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
15 oct. 2024 07h30 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
03 oct. 2024 09h02 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
03 oct. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
27 sept. 2024 10h22 HE
|
Knight Therapeutics
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...
Safety Shot Spins Off Caring Brands Business with Plans to Issue a Dividend to Shareholders
26 sept. 2024 09h15 HE
|
Safety Shot, Inc.
The Company is Divesting its Wellness Unit to Create Value for Shareholders and to Focus on Commercialization of its Safety Shot Dietary Supplement JUPITER, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --...